HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TYK MEDICINES-B

6.665

-0.305-4.38%

Volume:4.46M

Turnover:30.31M

Market Cap:2.53B

PE:-7.14

High:7.105

Open:6.775

Low:6.660

Close:6.970

52wk High:22.560

52wk Low:5.350

Shares:380.07M

HK Float Shares:375.46M

Volume Ratio:1.03

T/O Rate:1.19%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.934

ROE:-70.66%

ROA:-28.19%

PB:8.32

PE(LYR):-7.14

PS:20288.32

Loading ...

Overview Company News Filings

TYK MEDICINES-B Shares Surge Over 15% on Upcoming Commercialization of TY-9591 and Positive Clinical Data for Edotinib

TYK MEDICINES-B Shares Surge Over 6% on Positive Clinical Data for Brain Metastasis Drug, Anticipated Q3 Launch

TYK Medicines Convenes 15 July 2026 EGM to Secure Share-Issuance Mandate

Bulletin Express

TYK Medicines Seeks Shareholders’ Approval for 20% General Share Issuance Mandate

Bulletin Express

TYK Medicines Announces Extraordinary General Meeting

TYK Medicines Sets 10–15 July 2026 Book Closure to Determine EGM Voting Entitlements

Bulletin Express

TYK Medicines shareholders pass Articles of Association amendments at AGM

TYK Medicines Keeps Share Capital Steady at 380.07 Million H Shares in May; Public Float Meets 25% Rule

Bulletin Express

Major Breakthrough at ASCO 2026: TYK MEDICINES-B's Edotinib Achieves 95.5% Intracranial Objective Response Rate, Leading the Frontline Treatment for EGFR Lung Cancer Brain Metastases

TYK Medicines reports superior interim Phase II data for asandeutertinib versus osimertinib in first-line EGFR-mutant NSCLC with brain metastases

Bulletin Express

Key Phase II ESAONA Study Results for TYK MEDICINES-B's (02410) TY-9591 in First-Line NSCLC Brain Metastases Presented as Late-Breaking Abstract at 2026 ASCO

TYK Medicines says Phase II study shows asandeutertinib beats osimertinib on intracranial response in EGFR-mutant NSCLC with brain metastases

TYK Medicines Releases 2025 AGM Agenda Covering Profit Distribution, Share Mandates and Board Re-election

Bulletin Express

TYK Medicines to Seek 20% Share Issue Mandate, RMB300 Million Bank Lines and No-Dividend Plan at 23 June AGM

Bulletin Express

Insiders Could Have Profited By Holding onto TYK Medicines Shares Despite 12% Drop

Simply Wall St.

TYK Medicines Posts Stable Share Capital and Maintains Public Float in April 2026 Monthly Return

Bulletin Express

TYK Medicines-B 2025年研发推进加速，亏损收窄至3.06亿元，净资产维持正值

Bulletin Express

TYK Medicines publishes 2025 annual report

TYK MEDICINES-B's (02410) Self-Developed TY-3002 Monotherapy Demonstrates Outstanding Weight Loss Efficacy, Pioneering Next-Generation Oral GLP-1R Small Molecule Innovation

TYK Medicines Converts 4.61 Million Unlisted Shares Into H Shares, Registered Capital Rises to RMB 380.07 Million

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/02410/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02410","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02410\",,,,,undefined,":{"symbol":"02410","market":"HK","secType":"STK","nameCN":"TYK MEDICINES-B","latestPrice":6.665,"timestamp":1787299688005,"preClose":6.97,"halted":0,"volume":4463500,"delay":0,"changeRate":-0.04375896700143468,"floatShares":375457818,"shares":380065818,"eps":-0.9335100251707454,"marketStatus":"Market Closed","change":-0.305,"latestTime":"08-21 16:08:08","open":6.775,"high":7.105,"low":6.66,"amount":30308407,"amplitude":0.063845,"askPrice":6.67,"askSize":3500,"bidPrice":6.665,"bidSize":17000,"shortable":3,"etf":0,"ttmEps":-0.678546266433517,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":7,"adr":0,"listingDate":1724083200000,"exchange":"SEHK","adjPreClose":6.97,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":1.026139132850207,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02410\",,,,,undefined,":{"symbol":"02410","floatShares":375457818,"roa":"-28.19%","roe":"-70.66%","lyrEps":-0.93351,"volumeRatio":1.026139132850207,"shares":380065818,"dividePrice":0,"high":7.105,"amplitude":0.063845,"preClose":6.97,"low":6.66,"week52Low":5.35,"pbRate":"8.32","psRate":"20288.32","week52High":22.56,"institutionHeld":0,"latestPrice":6.665,"committee":0.658537,"eps":-0.9335100251707454,"divideRate":0,"volume":4463500,"delay":0,"ttmEps":-0.678546266433517,"open":6.775,"prevYearClose":13.11,"prevWeekClose":6.725,"prevMonthClose":6.81,"prevQuarterClose":5.73,"fiveDayClose":6.725,"twentyDayClose":6.86,"sixtyDayClose":8.48},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02410\",params:#limit:5,,,undefined,":[{"date":"2026-08-17","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1786930200000,"name":null,"time":"","dateTimestamp":1786896000000,"actualEps":null},{"date":"2026-03-30","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null},{"date":"2025-08-31","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756603800000,"name":null,"time":"","dateTimestamp":1756569600000,"actualEps":null},{"date":"2025-03-27","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743039000000,"name":null,"time":"","dateTimestamp":1743004800000,"actualEps":null},{"date":"2024-08-30","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724981400000,"name":null,"time":"","dateTimestamp":1724947200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02410\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02410\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02410\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02410","date":"2026-08-21","current":-9.822469,"percent":0.861789,"low":-45.171338,"twenty":-23.939778,"median":-17.197085,"eighty":-12.303816,"high":-6.195227,"avg":-18.106134,"sd":7.174161,"marketCap":2563850996},"quantilePoints":[{"date":"2024-08-23","current":-18.036629,"twenty":-16.647141,"median":-14.72623,"eighty":-12.008468,"marketCap":8010053668},{"date":"2024-08-30","current":-17.916348,"twenty":-18.108709,"median":-17.490261,"eighty":-14.277882,"marketCap":8010053668},{"date":"2024-09-06","current":-22.38992,"twenty":-20.387629,"median":-17.957821,"eighty":-15.985061,"marketCap":10531737231},{"date":"2024-09-13","current":-25.215246,"twenty":-24.52304,"median":-18.767123,"eighty":-16.911292,"marketCap":11829662594},{"date":"2024-09-20","current":-22.432724,"twenty":-24.518581,"median":-20.496807,"eighty":-17.208183,"marketCap":10587362603},{"date":"2024-09-27","current":-24.719835,"twenty":-24.497927,"median":-22.38992,"eighty":-17.671485,"marketCap":11736953639},{"date":"2024-10-04","current":-24.95032,"twenty":-24.87878,"median":-23.321155,"eighty":-17.932937,"marketCap":11792579012},{"date":"2024-10-10","current":-25.38933,"twenty":-24.941363,"median":-23.362473,"eighty":-17.973583,"marketCap":11922371548},{"date":"2024-10-18","current":-26.355956,"twenty":-25.311733,"median":-23.798709,"eighty":-18.108709,"marketCap":12311749157},{"date":"2024-10-25","current":-24.571342,"twenty":-25.374683,"median":-24.122054,"eighty":-18.545067,"marketCap":11477368567},{"date":"2024-11-01","current":-18.445843,"twenty":-25.311733,"median":-23.998666,"eighty":-18.584118,"marketCap":8621932768},{"date":"2024-11-08","current":-20.323115,"twenty":-25.278482,"median":-23.623818,"eighty":-17.973583,"marketCap":9456313359},{"date":"2024-11-15","current":-19.45318,"twenty":-25.171449,"median":-23.425489,"eighty":-18.108709,"marketCap":8955685004},{"date":"2024-11-22","current":-24.620137,"twenty":-24.988066,"median":-23.362473,"eighty":-18.406793,"marketCap":11329034239},{"date":"2024-11-29","current":-31.047836,"twenty":-25.311733,"median":-23.554037,"eighty":-18.584118,"marketCap":14277178993},{"date":"2024-12-06","current":-34.758675,"twenty":-25.786797,"median":-23.737743,"eighty":-19.168188,"marketCap":15945940174},{"date":"2024-12-13","current":-35.961329,"twenty":-26.0415,"median":-24.070769,"eighty":-19.324298,"marketCap":16465110319},{"date":"2024-12-20","current":-44.500897,"twenty":-30.298107,"median":-24.44033,"eighty":-19.494791,"marketCap":20284719244},{"date":"2024-12-27","current":-43.273475,"twenty":-31.455257,"median":-24.553474,"eighty":-19.619623,"marketCap":19709923726},{"date":"2025-01-03","current":-39.042242,"twenty":-33.760908,"median":-24.669986,"eighty":-19.709581,"marketCap":17800119264},{"date":"2025-01-10","current":-16.73771,"twenty":-34.083555,"median":-24.719835,"eighty":-19.709581,"marketCap":7602134269},{"date":"2025-01-17","current":-16.071561,"twenty":-33.760908,"median":-24.553474,"eighty":-18.860667,"marketCap":7305465614},{"date":"2025-01-24","current":-20.268382,"twenty":-32.413923,"median":-24.349989,"eighty":-19.230133,"marketCap":9270895450},{"date":"2025-01-28","current":-18.549699,"twenty":-31.591026,"median":-24.122054,"eighty":-18.549699,"marketCap":8529223814},{"date":"2025-02-07","current":-17.965815,"twenty":-31.472067,"median":-23.871541,"eighty":-18.275892,"marketCap":8214013368},{"date":"2025-02-14","current":-19.878813,"twenty":-31.451054,"median":-23.623818,"eighty":-18.275892,"marketCap":9066935750},{"date":"2025-02-21","current":-25.066745,"twenty":-31.047836,"median":-23.789321,"eighty":-18.32609,"marketCap":11495910358},{"date":"2025-02-28","current":-26.244856,"twenty":-30.411824,"median":-23.765234,"eighty":-18.39703,"marketCap":11996538712},{"date":"2025-03-07","current":-24.725844,"twenty":-30.135297,"median":-23.927628,"eighty":-18.445843,"marketCap":11347576030},{"date":"2025-03-14","current":-23.101371,"twenty":-29.84324,"median":-23.977848,"eighty":-18.549699,"marketCap":10605904394},{"date":"2025-03-21","current":-22.868028,"twenty":-28.789228,"median":-23.789321,"eighty":-18.691799,"marketCap":10494653649},{"date":"2025-03-28","current":-28.703724,"twenty":-28.703724,"median":-23.977848,"eighty":-19.110968,"marketCap":13146129748},{"date":"2025-04-03","current":-29.204856,"twenty":-29.744706,"median":-24.122054,"eighty":-19.131966,"marketCap":12070705875},{"date":"2025-04-11","current":-24.387234,"twenty":-29.307899,"median":-24.067881,"eighty":-19.145106,"marketCap":10012567086},{"date":"2025-04-17","current":-24.599189,"twenty":-28.955479,"median":-24.067881,"eighty":-19.224594,"marketCap":10123817831},{"date":"2025-04-25","current":-24.758022,"twenty":-28.755026,"median":-24.236021,"eighty":-19.282593,"marketCap":10197984995},{"date":"2025-05-02","current":-30.859428,"twenty":-28.772127,"median":-24.368612,"eighty":-19.308976,"marketCap":12738210348},{"date":"2025-05-09","current":-26.222368,"twenty":-28.789228,"median":-24.487968,"eighty":-19.376573,"marketCap":11477368567},{"date":"2025-05-16","current":-19.875071,"twenty":-28.703724,"median":-24.44033,"eighty":-19.45318,"marketCap":8770267095},{"date":"2025-05-23","current":-18.391406,"twenty":-28.460584,"median":-24.320388,"eighty":-19.147078,"marketCap":8139846205},{"date":"2025-05-30","current":-16.767615,"twenty":-28.328721,"median":-24.116277,"eighty":-18.777931,"marketCap":7453799941},{"date":"2025-06-06","current":-19.720458,"twenty":-27.077703,"median":-23.93026,"eighty":-18.847277,"marketCap":8788808886},{"date":"2025-06-13","current":-16.18601,"twenty":-26.697665,"median":-23.850097,"eighty":-18.709822,"marketCap":7216465018},{"date":"2025-06-20","current":-14.05098,"twenty":-26.664525,"median":-23.778892,"eighty":-18.426653,"marketCap":6252291891},{"date":"2025-06-27","current":-16.3221,"twenty":-26.630078,"median":-23.66211,"eighty":-18.32609,"marketCap":7283215465},{"date":"2025-07-04","current":-17.493079,"twenty":-26.41078,"median":-23.623818,"eighty":-18.194509,"marketCap":7806093968},{"date":"2025-07-11","current":-16.487526,"twenty":-26.267076,"median":-23.430941,"eighty":-17.964216,"marketCap":7349965912},{"date":"2025-07-18","current":-15.867745,"twenty":-26.226866,"median":-23.321155,"eighty":-17.866761,"marketCap":7068130691},{"date":"2025-07-25","current":-16.407488,"twenty":-26.143659,"median":-23.070409,"eighty":-17.335488,"marketCap":7335132480},{"date":"2025-08-01","current":-14.539711,"twenty":-26.072617,"median":-22.868028,"eighty":-17.325642,"marketCap":6459959949},{"date":"2025-08-08","current":-15.316665,"twenty":-25.987382,"median":-22.563641,"eighty":-17.04089,"marketCap":6822181433},{"date":"2025-08-15","current":-17.450454,"twenty":-25.968574,"median":-22.406203,"eighty":-16.915178,"marketCap":7760944003},{"date":"2025-08-22","current":-13.484776,"twenty":-25.95357,"median":-22.354126,"eighty":-16.718364,"marketCap":5978435317},{"date":"2025-08-29","current":-12.516323,"twenty":-25.925655,"median":-21.46252,"eighty":-16.486483,"marketCap":5575565550},{"date":"2025-09-05","current":-19.23268,"twenty":-25.919389,"median":-21.226743,"eighty":-16.486483,"marketCap":5883418862},{"date":"2025-09-12","current":-18.156363,"twenty":-25.850806,"median":-20.678772,"eighty":-16.541494,"marketCap":5564163575},{"date":"2025-09-19","current":-18.839434,"twenty":-25.807696,"median":-20.500943,"eighty":-16.56352,"marketCap":5769399117},{"date":"2025-09-26","current":-19.348832,"twenty":-25.743581,"median":-20.268382,"eighty":-16.654406,"marketCap":5910023469},{"date":"2025-10-03","current":-22.468168,"twenty":-25.650075,"median":-20.314843,"eighty":-16.707921,"marketCap":6879191305},{"date":"2025-10-10","current":-19.927643,"twenty":-25.596841,"median":-20.323115,"eighty":-16.732368,"marketCap":6092455062},{"date":"2025-10-17","current":-19.134493,"twenty":-25.519561,"median":-20.155539,"eighty":-16.749672,"marketCap":5845412280},{"date":"2025-10-24","current":-17.635142,"twenty":-25.404318,"median":-19.980008,"eighty":-16.781291,"marketCap":5389333299},{"date":"2025-10-31","current":-19.024541,"twenty":-25.400784,"median":-19.927643,"eighty":-16.830147,"marketCap":5822608331},{"date":"2025-11-07","current":-17.694439,"twenty":-25.37593,"median":-19.869193,"eighty":-16.945559,"marketCap":5412137248},{"date":"2025-11-14","current":-17.099248,"twenty":-25.321084,"median":-19.741813,"eighty":-16.951188,"marketCap":5244908288},{"date":"2025-11-21","current":-15.19815,"twenty":-25.311733,"median":-19.694587,"eighty":-16.919035,"marketCap":4659606928},{"date":"2025-11-28","current":-16.711808,"twenty":-25.293455,"median":-19.641679,"eighty":-16.730587,"marketCap":5142290517},{"date":"2025-12-05","current":-17.262657,"twenty":-25.275139,"median":-19.635782,"eighty":-16.587841,"marketCap":5320921452},{"date":"2025-12-12","current":-16.160016,"twenty":-25.213434,"median":-19.544821,"eighty":-16.497144,"marketCap":4990264190},{"date":"2025-12-19","current":-16.355316,"twenty":-25.19336,"median":-19.414876,"eighty":-16.454475,"marketCap":5062476695},{"date":"2025-12-24","current":-15.692499,"twenty":-25.154877,"median":-19.348832,"eighty":-16.406101,"marketCap":4872443786},{"date":"2026-01-02","current":-15.765099,"twenty":-25.10227,"median":-19.292077,"eighty":-16.35327,"marketCap":4914251026},{"date":"2026-01-09","current":-17.392186,"twenty":-25.070347,"median":-19.235279,"eighty":-16.345574,"marketCap":5434941197},{"date":"2026-01-16","current":-16.438751,"twenty":-25.06473,"median":-19.137216,"eighty":-16.35327,"marketCap":5153692492},{"date":"2026-01-23","current":-15.75073,"twenty":-25.023112,"median":-19.120814,"eighty":-16.314941,"marketCap":4933254317},{"date":"2026-01-30","current":-15.280433,"twenty":-24.971672,"median":-19.022068,"eighty":-16.22453,"marketCap":4807832597},{"date":"2026-02-06","current":-15.542994,"twenty":-24.952303,"median":-18.937078,"eighty":-16.152588,"marketCap":4902849052},{"date":"2026-02-13","current":-15.334427,"twenty":-24.923448,"median":-18.860882,"eighty":-16.099082,"marketCap":4864842470},{"date":"2026-02-20","current":-15.572498,"twenty":-24.905533,"median":-18.847277,"eighty":-16.071561,"marketCap":4933254317},{"date":"2026-02-27","current":-14.952615,"twenty":-24.827654,"median":-18.801141,"eighty":-15.988536,"marketCap":4788829306},{"date":"2026-03-06","current":-13.279596,"twenty":-24.77147,"median":-18.709822,"eighty":-15.892604,"marketCap":4218730579},{"date":"2026-03-13","current":-12.861452,"twenty":-24.760877,"median":-18.616931,"eighty":-15.828013,"marketCap":4104710834},{"date":"2026-03-20","current":-12.157235,"twenty":-24.758022,"median":-18.440891,"eighty":-15.765099,"marketCap":3865269369},{"date":"2026-03-27","current":-12.164275,"twenty":-24.758022,"median":-18.409208,"eighty":-15.692499,"marketCap":3857668052},{"date":"2026-04-02","current":-12.25818,"twenty":-24.73228,"median":-18.399621,"eighty":-15.606124,"marketCap":4180723998},{"date":"2026-04-10","current":-12.412577,"twenty":-24.72344,"median":-18.391406,"eighty":-15.554796,"marketCap":4266032641},{"date":"2026-04-17","current":-12.351427,"twenty":-24.717087,"median":-18.309793,"eighty":-15.461655,"marketCap":4246798950},{"date":"2026-04-24","current":-11.422185,"twenty":-24.709149,"median":-18.216326,"eighty":-15.337994,"marketCap":3927519681},{"date":"2026-04-30","current":-11.117278,"twenty":-24.702871,"median":-18.174743,"eighty":-15.304685,"marketCap":3823657750},{"date":"2026-05-08","current":-10.777891,"twenty":-24.684547,"median":-18.056929,"eighty":-15.189837,"marketCap":3719795820},{"date":"2026-05-15","current":-9.293361,"twenty":-24.617578,"median":-17.965815,"eighty":-15.119492,"marketCap":3215873118},{"date":"2026-05-22","current":-8.991533,"twenty":-24.605712,"median":-17.939574,"eighty":-15.043492,"marketCap":3104317711},{"date":"2026-05-29","current":-10.14843,"twenty":-24.599189,"median":-17.918048,"eighty":-14.961326,"marketCap":3515918696},{"date":"2026-06-05","current":-8.237808,"twenty":-24.571342,"median":-17.89208,"eighty":-14.895383,"marketCap":2858126467},{"date":"2026-06-12","current":-7.644268,"twenty":-24.535606,"median":-17.732128,"eighty":-14.684931,"marketCap":2650402606},{"date":"2026-06-18","current":-6.884404,"twenty":-24.459385,"median":-17.688347,"eighty":-14.384241,"marketCap":2392671147},{"date":"2026-06-26","current":-6.195227,"twenty":-24.397853,"median":-17.672452,"eighty":-13.470121,"marketCap":2142633166},{"date":"2026-07-03","current":-7.179757,"twenty":-24.364887,"median":-17.499062,"eighty":-13.369605,"marketCap":2484992864},{"date":"2026-07-10","current":-8.078806,"twenty":-24.314468,"median":-17.476751,"eighty":-13.262753,"marketCap":2792731918},{"date":"2026-07-17","current":-8.127776,"twenty":-24.232724,"median":-17.419476,"eighty":-13.079412,"marketCap":2819659085},{"date":"2026-07-24","current":-7.604914,"twenty":-24.150839,"median":-17.377721,"eighty":-12.93356,"marketCap":2638862391},{"date":"2026-07-31","current":-7.53517,"twenty":-24.119743,"median":-17.333807,"eighty":-12.87079,"marketCap":2619628700},{"date":"2026-08-07","current":-7.625479,"twenty":-24.07756,"median":-17.320685,"eighty":-12.528428,"marketCap":2656172713},{"date":"2026-08-14","current":-7.417307,"twenty":-24.00283,"median":-17.276309,"eighty":-12.375887,"marketCap":2586931426},{"date":"2026-08-21","current":-10.34776,"twenty":-23.939778,"median":-17.197085,"eighty":-12.303816,"marketCap":2563850996}],"updateTime":1787458749063},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02410\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1176636503","title":"TYK MEDICINES-B Shares Surge Over 15% on Upcoming Commercialization of TY-9591 and Positive Clinical Data for Edotinib","url":"https://stock-news.laohu8.com/highlight/detail?id=1176636503","media":"Stock News","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176636503?lang=en_us&edition=fundamental","pubTime":"2026-07-14 10:44","pubTimestamp":1783997070,"startTime":"0","endTime":"0","summary":"Shares of TYK MEDICINES-B (ASX: 02410) surged more than 15% during the trading session. At the time of writing, the stock was up 12.68% to HK$7.82, with a turnover of HK$49.356 million. Positive...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK4588","BK1161","BK1515","BK4585","09939","BK1574","KCAI","159938","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183710760","title":"TYK MEDICINES-B Shares Surge Over 6% on Positive Clinical Data for Brain Metastasis Drug, Anticipated Q3 Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=1183710760","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183710760?lang=en_us&edition=fundamental","pubTime":"2026-07-08 11:35","pubTimestamp":1783481755,"startTime":"0","endTime":"0","summary":"Shares of TYK MEDICINES-B (ASX: 02410) have risen more than 6%. At the time of writing, the stock is up 5.63% to HK$6.76, with a turnover of HK$11.09 million. The positive movement follows the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","159938","BK4585","VXUS","IPOS","BK1161","02410","KCAI","BK1515","09939","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127030077","title":"TYK Medicines Convenes 15 July 2026 EGM to Secure Share-Issuance Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=1127030077","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127030077?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:25","pubTimestamp":1782735921,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (浙江同源康醫藥股份有限公司) has issued a notice and proxy form for its first extraordinary general meeting (EGM) of 2026, scheduled for 2:00 p.m. on Wednesday, 15 July 2026. The session will...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109519601","title":"TYK Medicines Seeks Shareholders’ Approval for 20% General Share Issuance Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=1109519601","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109519601?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:05","pubTimestamp":1782734754,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. will convene its first extraordinary general meeting of 2026 on 15 July 2026 at 2:00 p.m. in Shanghai. The sole agenda item is a special resolution authorizing the Board to issue...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647379548","title":"TYK Medicines Announces Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2647379548","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647379548?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:58","pubTimestamp":1782734304,"startTime":"0","endTime":"0","summary":"TYK Medicines announces extraordinary general meetingTYK Medicines will hold an extraordinary general meeting in Shanghai on July 15, 2026.Shareholders will vote on a general mandate authorizing the b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDLbF8dZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152333401","title":"TYK Medicines Sets 10–15 July 2026 Book Closure to Determine EGM Voting Entitlements","url":"https://stock-news.laohu8.com/highlight/detail?id=1152333401","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152333401?lang=en_us&edition=fundamental","pubTime":"2026-06-24 16:44","pubTimestamp":1782290682,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. will close its register of members from Friday, 10 July 2026 to Wednesday, 15 July 2026, inclusive. The suspension of share transfers is intended to establish shareholder...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645838829","title":"TYK Medicines shareholders pass Articles of Association amendments at AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2645838829","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645838829?lang=en_us&edition=fundamental","pubTime":"2026-06-23 18:44","pubTimestamp":1782211490,"startTime":"0","endTime":"0","summary":"Shareholders passed amendments to TYK Medicines’ articles of association at the 2025 AGM on June 23, 2026.The special resolution drew 8,036,001 votes for , 19,500 against , 10,500 abstentions .The meeting also rejected a separate share-issuance mandate, with 41.56% in favor and 58.04% abstaining.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL4kNSF6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104429351","title":"TYK Medicines Keeps Share Capital Steady at 380.07 Million H Shares in May; Public Float Meets 25% Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=1104429351","media":"Bulletin Express","labels":["SGX","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104429351?lang=en_us&edition=fundamental","pubTime":"2026-06-02 18:44","pubTimestamp":1780397051,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (PRC-incorporated, listed in Hong Kong) reported no change in its share structure for the month ended 31 May 2026, according to the Monthly Return filed on 2 June 2026. Registered...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134286006","title":"Major Breakthrough at ASCO 2026: TYK MEDICINES-B's Edotinib Achieves 95.5% Intracranial Objective Response Rate, Leading the Frontline Treatment for EGFR Lung Cancer Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=1134286006","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134286006?lang=en_us&edition=fundamental","pubTime":"2026-06-01 10:13","pubTimestamp":1780280012,"startTime":"0","endTime":"0","summary":"A key clinical breakthrough was announced at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. TYK MEDICINES-B (02410), a Hong Kong-listed innovative pharmaceutical company,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","159938","BK1515","BK1161","09939","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192011753","title":"TYK Medicines reports superior interim Phase II data for asandeutertinib versus osimertinib in first-line EGFR-mutant NSCLC with brain metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=1192011753","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192011753?lang=en_us&edition=fundamental","pubTime":"2026-05-31 18:24","pubTimestamp":1780223069,"startTime":"0","endTime":"0","summary":"TYK Medicines (02410.HK) released interim results from the pivotal Phase II ESAONA study comparing asandeutertinib (TY-9591) with osimertinib as first-line therapy for epidermal growth factor...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151955380","title":"Key Phase II ESAONA Study Results for TYK MEDICINES-B's (02410) TY-9591 in First-Line NSCLC Brain Metastases Presented as Late-Breaking Abstract at 2026 ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=1151955380","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151955380?lang=en_us&edition=fundamental","pubTime":"2026-05-31 18:20","pubTimestamp":1780222827,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) announced that the interim analysis results from the pivotal Phase II ESAONA study for its self-developed drug, TY-9591 (mesylate edotinib tablets), versus osimertinib in the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1161","BK1515","159938","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639600295","title":"TYK Medicines says Phase II study shows asandeutertinib beats osimertinib on intracranial response in EGFR-mutant NSCLC with brain metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2639600295","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639600295?lang=en_us&edition=fundamental","pubTime":"2026-05-31 18:11","pubTimestamp":1780222303,"startTime":"0","endTime":"0","summary":"TYK Medicines says Phase II study shows asandeutertinib beats osimertinib on intracranial response in EGFR-mutant NSCLC with brain metastases. TYK Medicines highlighted interim results from its pivotal Phase II ESAONA trial of asandeutertinib in EGFR-mutant NSCLC with brain metastases.Results were already presented as a late-breaking oral abstract at the 2026 ASCO Annual Meeting.The study showed stronger control of brain metastases versus AstraZeneca’s osimertinib, with a manageable safety profile.Systemic disease control also favored asandeutertinib, supporting a potential new first-line positioning in this patient group.An NDA has been accepted in China and placed into a priority review pathway, with longer-term follow-up still ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260531:nNDL3gRqnT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149674578","title":"TYK Medicines Releases 2025 AGM Agenda Covering Profit Distribution, Share Mandates and Board Re-election","url":"https://stock-news.laohu8.com/highlight/detail?id=1149674578","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149674578?lang=en_us&edition=fundamental","pubTime":"2026-05-22 16:45","pubTimestamp":1779439549,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. has issued the proxy form for its 2025 Annual General Meeting scheduled for 2:00 p.m. on 23 June 2026 at 8/F, Building T2, China Eastern Binjiang Center, Xuhui District, Shanghai....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167825735","title":"TYK Medicines to Seek 20% Share Issue Mandate, RMB300 Million Bank Lines and No-Dividend Plan at 23 June AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=1167825735","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167825735?lang=en_us&edition=fundamental","pubTime":"2026-05-22 16:44","pubTimestamp":1779439446,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (TYK Medicines) released its 2025 AGM circular dated 22 May 2026, detailing resolutions to be tabled on 23 June 2026 in Shanghai. Financial Reporting and Dividend   • The audited...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635776438","title":"Insiders Could Have Profited By Holding onto TYK Medicines Shares Despite 12% Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2635776438","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635776438?lang=en_us&edition=fundamental","pubTime":"2026-05-14 11:15","pubTimestamp":1778728529,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc's (HKG:2410) value has fallen 12% in the last week, but insiders who sold CN¥4.2m worth of stock...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2410/tyk-medicines-shares/news/insiders-could-have-profited-by-holding-onto-tyk-medicines-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2410/tyk-medicines-shares/news/insiders-could-have-profited-by-holding-onto-tyk-medicines-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","MDCO","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169008621","title":"TYK Medicines Posts Stable Share Capital and Maintains Public Float in April 2026 Monthly Return","url":"https://stock-news.laohu8.com/highlight/detail?id=1169008621","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169008621?lang=en_us&edition=fundamental","pubTime":"2026-05-06 17:23","pubTimestamp":1778059403,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (H-share; HKEX: 02410) filed its Monthly Return for Equity Issuer covering the period ended 30 April 2026, confirming no changes to share capital and continued compliance with...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120304539","title":"TYK Medicines-B 2025年研发推进加速，亏损收窄至3.06亿元，净资产维持正值","url":"https://stock-news.laohu8.com/highlight/detail?id=1120304539","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120304539?lang=en_us&edition=fundamental","pubTime":"2026-04-29 16:59","pubTimestamp":1777453145,"startTime":"0","endTime":"0","summary":"TYK Medicines-B于本年度进一步聚焦癌症领域的差异化创新靶向治疗，专注于小分子抗肿瘤药物的研发与商业化推进，共拥有10项在研新药，其中5款处于临床阶段，4款处于临床前或早期临床阶段。核心产品TY-9591围绕EGFR基因突变相关的非小细胞肺癌展开多项临床试验，涵盖针对脑转移的一线单药治疗、与培美曲塞及顺铂或卡铂联合用药的二、三期试验及EGFR...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"TYK Medicines-B 2025年研发推进加速，亏损收窄至3.06亿元，净资产维持正值","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631560423","title":"TYK Medicines publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2631560423","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631560423?lang=en_us&edition=fundamental","pubTime":"2026-04-29 16:43","pubTimestamp":1777452198,"startTime":"0","endTime":"0","summary":"TYK Medicines annual report for 2025 outlined progress toward first commercialization, led by core oncology asset TY-9591.TY-9591 conditional NDA for first-line treatment of brain metastases in EGFR-mutant lung cancer entered priority review in January 2026, with marketing approval expected in Q3 2026.Enrollment in registrational Phase III trial of TY-9591 in first-line EGFR L858R-mutant NSCLC reached 548 patients in April 2026, with full enrollment expected in Q4 2026 and NDA targeted for 2028.Pipeline execution extended beyond TY-9591, with TY-302 in Phase II for breast cancer, TY-2136b in Phase I in US, TY-1054 dosing first patient in March 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the origina","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL4lSxhd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181264075","title":"TYK MEDICINES-B's (02410) Self-Developed TY-3002 Monotherapy Demonstrates Outstanding Weight Loss Efficacy, Pioneering Next-Generation Oral GLP-1R Small Molecule Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=1181264075","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181264075?lang=en_us&edition=fundamental","pubTime":"2026-04-16 17:13","pubTimestamp":1776330825,"startTime":"0","endTime":"0","summary":"The weight loss sector, a core focus in global innovative drug development, continues to attract leading industry players. Recently, TYK MEDICINES-B (02410) announced the formal nomination of its...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TY","BK1515","09939","GLP","159938","BK1161","BK4144","02410","BK1574","BK4590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116554785","title":"TYK Medicines Converts 4.61 Million Unlisted Shares Into H Shares, Registered Capital Rises to RMB 380.07 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1116554785","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116554785?lang=en_us&edition=fundamental","pubTime":"2026-04-08 18:02","pubTimestamp":1775642537,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (TYK Medicines) reported in its resubmitted Monthly Return for the period ended 31 March 2026 that it completed the conversion of 4.61 million unlisted shares into the same number...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":61,"code":"91000000","status":"200"}]}}